Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Thymalfasin Combined With Chemotherapy and Immunotherapy for Neoadjuvant Treatment of Triple-Negative Breast Cancer：A Prospective, Open-Label, Single-Center, Phase II, Randomized Controlled Clinical Study

NCT07884201 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT07884201
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07884201 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Thymalfasin Combined With Chemotherapy and Immunotherapy for Neoadjuvant Treatment of Triple-Negative Breast Cancer：A Prospective, Open-Label, Single-Center, Phase II, Randomized Controlled Clinical Study
Lead sponsor
Fudan University
Phase
Phase 2
Overall status
Not yet recruiting
Start date
November 8, 2026
Completion date
October 8, 2031
Enrollment
572 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, immunotherapy, tnbc - triple-negative breast cancer